

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Habib Zaghouani)	ATTORNEY DOCKET:	07316.0002.PCUS00
)		
SERIAL NO.:	10/510,411)	GROUP ART UNIT:	1644
)		
FILED:	April 8, 2003)	EXAMINER:	Gerald R. Ewoldt
)		
TITLE:	Treatment of Type-1 Diabetes Before and After Expression of Predisposition Markers			
DATE:	May 1, 2008		CUSTOMER NO.:	22930
CONF NO.:	8513			

Commissioner for Patents
PO BOX 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97(c)

Sir:

Applicants hereby submit copies of patents, publications and/or other information of which they are aware and which may be related to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56 and §§ 1.97-1.98, as supplemented by MPEP §609. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Applicant respectfully requests that the Examiner consider the listed documents and evidence the consideration of relevant portions thereof by making appropriate notations on the attached form.

Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.


This information disclosure statement is being filed after the period specified in 35 C.F.R. § 1.97(b) but prior to the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution.

This IDS is accompanied by a statement under 35 U.S.C. 1.97(e).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the person signing the certification after making reasonable inquiring, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists. Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application.

Respectfully submitted,



David B. Fournier
Reg. No. 51,696

Date: May 1, 2008

CUSTOMER NUMBER 22930
HOWREY LLP

Telephone: (312) 846-5621
Facsimile: (312) 264-0366

Enclosures:
Form PTO-1449
Copies of cited documents

HOWREY LLP
ATTN: Docketing Department
2941 Fairview Park Drive, Suite 200
Falls Church, VA 22042-9922
Telephone No.: (703) 663-3600
Facsimile No.: (703) 336-6950